Related Experiment Video
Updated: Aug 12, 2026

05:05
Ultrasound Cyclo Plasty in Eyes with Glaucoma
Published on: January 26, 2018
Ahmed valve implant for uncontrolled uveitic glaucoma
F Gil-Carrasco1, E Salinas-VanOrman, C Recillas-Gispert
1Hospital Dr. Luis Sánchez Bulnes, Asociación para Evitar la Ceguera en México, IAP, México.
Ocular Immunology and Inflammation
|November 3, 1998
Summary
The Ahmed valve implant shows promise for uncontrolled uveitic glaucoma, with a 57% success rate in high-risk patients. This glaucoma surgery effectively reduced intraocular pressure and medication use in the study.
Area of Science:
- Ophthalmology
- Glaucoma Surgery
- Uveitic Glaucoma
Background:
- Uveitic glaucoma presents a significant challenge due to uncontrolled intraocular pressure (IOP).
- High-risk patients, often with prior cataract and multiple glaucoma surgeries, require effective treatment options.
Purpose of the Study:
- To evaluate the efficacy of the Ahmed valve implant in managing uncontrolled uveitic glaucoma.
- To assess the safety and outcomes of Ahmed valve implantation in a cohort of high-risk patients.
Main Methods:
- Retrospective review of medical records for patients with uncontrolled uveitic glaucoma who underwent Ahmed valve implant surgery.
- Success defined by IOP between 4-22 mmHg without further glaucoma surgery, hypotony, phthisis, or vision loss.
Main Results:
- The Ahmed valve implant achieved a success rate of 57.14% (8 out of 14 eyes).
- Mean IOP significantly decreased from 32.64 mmHg preoperatively to 17.57 mmHg postoperatively (p < 0.0001).
- Postoperative medication use decreased from a mean of 2.78 to 0.71 (p < 0.0001).
Conclusions:
- The Ahmed valve implant is a viable and safe alternative for high-risk patients with uncontrolled uveitic glaucoma.
- The procedure demonstrated significant IOP reduction and decreased medication dependency in this challenging patient group.
Related Concept Videos
Glaucoma: Overview
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
Hemodialysis I: Introduction
Hemodialysis (HD) is a medical treatment that artificially removes waste products, excess fluids, and toxins from the blood when the kidneys are no longer able to perform these functions effectively. In this process, blood is filtered through a semipermeable membrane, allowing for the selective removal of waste while preserving necessary components like blood cells and proteins. Hemodialysis is typically performed in patients with end-stage renal disease (ESRD) or severe kidney...

